Parnax Lab Ltd. (PARNAXLAB): Parnax Lab Share Price Falls 9.93% to Rs 116.50, Stock in Focus

Parnax Lab Ltd. fell to Rs 116.50, down 9.93% today. The micro-cap Healthcare stock has a market capitalisation of Rs 148.57 crore.

Parnax Lab Share Price is at Rs 116.50 on 17 August 2026, down Rs 12.85 or 9.93% from the previous close of Rs 129.35. With a market capitalisation of Rs 148.57 crore, the Healthcare counter has entered the session as a notable top decliner after a sharp same-day share price decline on BSE. For investors tracking Parnax Lab Share Price Today and Parnax Lab Stock News, the key verified takeaway is simple: the stock has recorded a sizeable single-day price fall that is large enough to qualify under the event screen for its Micro Cap category.

The supplied data confirms the move in price, the trading range and the turnover, but it does not establish a company-specific catalyst behind the fall. That makes today’s market move more about observed price action than confirmed corporate news. The stock opened at Rs 118, touched a high of Rs 118 and a low of Rs 114.50, showing that selling pressure was visible almost from the start of trade.

For readers searching Parnax Lab Share Price, Parnax Lab Share Price Today or Parnax Lab Stock News, the more useful question is what this decline says about participation, valuation, profitability and industry positioning. Univest examines the day’s price action first, then places the stock in a broader fundamental, peer and sector context so investors can monitor the right data points next.

Parnax Lab Ltd. (PARNAXLAB) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 116.5
Previous Close	Rs 129.35
Today's Change	Rs -12.85 (-9.93%)
Day Open	Rs 118
Day High	Rs 118
Day Low	Rs 114.5
Current Volume (BSE)	4,950
BSE Traded Volume	4,950
Combined NSE + BSE Volume	4,950
Turnover	Rs 0.06 crore
Market Capitalisation	Rs 148.57 crore
Market Cap Category	Micro Cap

Parnax Lab Ltd. (PARNAXLAB) traded at Rs 116.5. versus the previous close of Rs 129.35, a fall of 9.93%. The stock opened at Rs 118, reached Rs 118, touched Rs 114.5. Reported volume was 4,950.

Parnax Lab Ltd. (PARNAXLAB) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 148.57 crore
P/E Ratio	16.63x
P/B Ratio	1.55x
ROE	-1.11%
ROCE	5.83%
EPS	Rs 7.78
Dividend Yield	0%

Parnax Lab Ltd. was valued at a P/E ratio of 16.63x, a P/B ratio of 1.55x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of -1.11% and ROCE of 5.83%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Per-share and shareholder-return metrics included EPS of Rs 7.78, dividend yield of 0%. Dividend yield is a current or historical ratio and does not guarantee future distributions.

Parnax Lab Fundamental Analysis starts with scale and valuation. The company’s market capitalisation stands at Rs 148.57 crore, which places it slightly above the industry median market cap of Rs 137.80 crore within the supplied same-industry benchmark set of 139 companies. Its price-to-earnings ratio is 16.63, while the price-to-book ratio is 1.55. In isolation, those numbers only describe valuation; they become more meaningful when compared with peers and industry benchmarks later in this article.

Profitability metrics are mixed. Return on equity is -1.11%, indicating that shareholder returns on the reported base are negative, while return on capital employed is 5.83%, which is positive but not especially high relative to the benchmark data. This gap matters because ROE reflects returns attributable to equity holders, whereas ROCE shows how efficiently the broader capital base is being used. Investors reading Parnax Lab Fundamental Analysis should therefore note that the company is not showing strong profitability on the supplied ratios despite trading at a positive earnings multiple.

EPS is Rs 7.78, which represents earnings attributable to each share on the supplied basis. That helps explain why the stock still carries a P/E ratio of 16.63 despite weak ROE. Dividend yield is 0, which means the current historical payout relative to the share price is nil in the supplied dataset. For investors comparing income characteristics across Healthcare names, that places the stock in a non-yielding bucket at present.

Overall, the fundamentals offer a measured rather than aggressive case for investor attention. Parnax Lab Share Price has fallen sharply today, but the available financial ratios do not describe a high-return business in the same way some peers do. At the same time, valuation is not at the upper end of the industry range. That combination makes ownership structure less of a story today and shifts attention toward relative positioning within Pharmaceuticals & Drugs.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	16.63x
Benchmark Median P/E	26.47x
Benchmark Average P/E	40.28x
Benchmark P/E Range	2.98x to 361.02x
Company P/B Ratio	1.55x
Benchmark Median P/B	1.77x
Company ROE	-1.11%
Benchmark Median ROE	9.91%
Company ROCE	5.83%
Benchmark Median ROCE	12.79%
Company Market Capitalisation	Rs 148.57 crore
Benchmark Median Market Cap	Rs 137.8 crore

Parnax Lab Ltd. (PARNAXLAB) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Parnax Lab Ltd. (PARNAXLAB) has a P/E ratio of 16.63x, which is below the benchmark median of 26.47x, a difference of -37.17%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Parnax Lab Ltd. (PARNAXLAB) has a ROE of -1.11%, which is below the benchmark median of 9.91%, a difference of -111.2%. Parnax Lab Ltd. (PARNAXLAB) has a ROCE of 5.83%, which is below the benchmark median of 12.79%, a difference of -54.42%.

Track today's top decliners through the Univest top decliners screener. The peer table below provides the company-level comparison.

Parnax Lab operates in Healthcare, specifically the Pharmaceuticals & Drugs industry, and the benchmark used here covers 139 companies in the same industry. That context matters because Parnax Lab Share Price is reacting within a sector where valuation and profitability vary widely, from low-single-digit P/E levels to very elevated multiples.

The company’s P/E ratio of 16.63 sits below the same-industry median of 26.47 and well below the average of 40.28 across 105 companies with available P/E data. The industry P/E range is broad, from 2.98 to 361.02, so Parnax Lab is not positioned near the expensive end of the sector on this metric. Its P/B ratio of 1.55 is also below the industry median of 1.77 and below the average of 2.33 across 138 companies, with the reported range stretching from -21.33 to 27.19.

Profitability tells a more restrained story. Parnax Lab’s ROE of -1.11% is below the industry median of 9.91% and below the average of 7.30. Its ROCE of 5.83% is also below the median of 12.79% and the average of 14.83. In other words, the stock’s valuation multiples are lower than central sector benchmarks, but so are its profitability measures. That balance is important for anyone reading Parnax Lab Share Price News and trying to decide whether today’s decline reflects an already modest valuation profile or concerns around quality metrics.

On size, the company’s market capitalisation of Rs 148.57 crore is above the industry median of Rs 137.80 crore but far below the industry average of Rs 481.52 crore and the benchmark maximum of Rs 2,985.15 crore. Univest reads this as a smaller listed Pharmaceuticals & Drugs name whose valuation is below benchmark medians, while operating returns remain below benchmark profitability levels.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Dishman Carbogen Amcis Ltd.	DCAL	2,985.15	184.72	0.45	-2.89	-0.26
Beta Drugs Ltd.	BETA	2,827.67	68.16	6.74	18.65	22.17
Hikal Ltd.	HIKAL	2,686.72	0	2.26	15.22	16.15
Ind-Swift Laboratories Ltd.	INDSWFTLAB	2,645.37	46.15	1.77	-0.78	8.31
Fredun Pharmaceuticals Ltd.	FREDUN	2,559.68	58.41	8.73	11.42	13.15

Parnax Lab Ltd. (PARNAXLAB) has a P/E ratio of 16.63x compared with the displayed peer median of 58.41x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of -1.11% compares with a peer median of 11.42% across the companies shown in the table. ROCE stood at 5.83% versus the displayed peer median of 13.15%, providing a capital-efficiency comparison. Parnax Lab Ltd. (PARNAXLAB) has a market capitalisation of Rs 148.57 crore. Among the 5 peers shown, 5 have a larger market capitalisation.

Against supplied listed peers, Parnax Lab sits toward the lower end of the valuation and profitability spectrum in some respects, though not in all. Its market capitalisation of Rs 148.57 crore is far smaller than every named peer in the comparison set, where market values range from Rs 2,139.20 crore for NGL Fine-Chem Ltd. to Rs 2,985.15 crore for Dishman Carbogen Amcis Ltd. That gap immediately marks Parnax Lab as a much smaller company than the peer basket most investors would use for relative screening.

On P/E, Parnax Lab trades at 16.63, which is below Venus Remedies at 20.56, Ind-Swift Laboratories at 46.15, Fredun Pharmaceuticals at 58.41, Beta Drugs at 68.16, Sai Parenteral’s at 171 and Dishman Carbogen Amcis at 184.72. Some peers do not have P/E figures displayed, but within the available set, Parnax Lab appears lower-valued on earnings multiple alone.

That lower multiple should be read alongside profitability. Parnax Lab’s ROE of -1.11% is weaker than Beta Drugs at 18.65%, Hikal at 15.22%, Fredun Pharmaceuticals at 11.42%, Sai Parenteral’s at 13.90%, Venus Remedies at 9.85% and NGL Fine-Chem at 27.90%. It is stronger than Dishman Carbogen Amcis at -2.89% and below Ind-Swift Laboratories at -0.78%. On ROCE, Parnax Lab at 5.83% trails Beta Drugs, Hikal, Fredun, Sai Parenteral’s, Venus Remedies and NGL Fine-Chem, while sitting above Panacea Biotec at 5.36% and Dishman Carbogen Amcis at -0.26%.

The P/B ratio of 1.55 is above Dishman Carbogen Amcis at 0.45 but below Hikal at 2.26, Panacea Biotec at 2.90, Sai Parenteral’s at 3.13, Venus Remedies at 3.48, NGL Fine-Chem at 6.15, Beta Drugs at 6.74 and Fredun Pharmaceuticals at 8.73. Univest therefore sees Parnax Lab Share Price as relatively lower-valued than many peers, but that comes with weaker return ratios than several names in the same peer group.

Why Investors Are Watching Parnax Lab

Parnax Lab Share Price is being watched because today’s fall is significant enough to stand out within the Micro Cap space, while the stock also presents a clear valuation-versus-profitability contrast. The price move is sharp, the liquidity is limited, and the industry comparison shows that the company trades below benchmark valuation medians even though its return ratios are also below sector norms. For market participants scanning Top Losers Today and Stocks in News, that combination is usually enough to keep the counter on watchlists.

• Price action: The stock fell 9.93% to Rs 116.50 from Rs 129.35, with the day’s high equal to the open at Rs 118.
• Trading range: The intraday low of Rs 114.50 shows the counter stayed under pressure through the session range captured in the data.
• Liquidity: Volume was 4,950 shares on BSE with turnover of Rs 0.06 crore, highlighting a relatively thinly traded micro-cap setup.
• Valuation: P/E at 16.63 and P/B at 1.55 are below same-industry medians of 26.47 and 1.77.
• Profitability: ROE of -1.11% and ROCE of 5.83 are below industry medians of 9.91% and 12.79.

What investors may monitor next is whether Parnax Lab Share Price stabilises within its current range and how the valuation discount is weighed against below-benchmark returns. In Univest coverage, that makes the stock relevant as a data-led watchlist candidate in the Healthcare basket, without turning the move into a directional call.

About Parnax Lab

Parnax Lab Ltd. is placed within the Healthcare sector and the Pharmaceuticals & Drugs industry in the supplied classification. That means the company is being assessed alongside other listed pharmaceutical and drug businesses for valuation, profitability and market-cap comparisons. Even without a longer business description in the current dataset, that industry context is useful because it places the company within a segment where earnings multiples, book-value multiples and capital returns can differ sharply from one listed player to another.

The benchmark universe used in this analysis includes 139 companies from the same industry, ranging from very small listed entities to firms with market capitalisations running into several thousand crore rupees. Within that context, Parnax Lab’s market capitalisation of Rs 148.57 crore places it as a smaller listed participant in its industry rather than as a large sector heavyweight. For readers looking up Parnax Lab Stock News, Parnax Lab Share News or broader Company News, that size context matters because price moves in smaller pharmaceutical counters can look more pronounced than in larger names.

On the available numbers, the company currently stands out less for scale and more for how its valuation compares with industry medians. That is why Parnax Lab Share Price has become the main focal point today: the stock’s market move is sharp, and the underlying financial ratios place it in a lower-valued but also lower-profitability pocket of the Healthcare universe.

Track Parnax Lab Share Price on Univest

Use Parnax Lab Ltd. (PARNAXLAB) live share-price page, Univest top decliners screener, Univest market blogs to review live stock data, top decliners lists and related market analysis.

Investors following Parnax Lab Share Price can track live market data and broader stock analysis on Univest. The platform helps users monitor share price movements, market capitalisation, valuation ratios such as P/E and P/B, profitability indicators including ROE and ROCE, and 52-week market context where available. Readers using Univest can also follow shareholding pattern data, technical indicators, sector comparisons and stock performance updates across listed companies.

For anyone searching Parnax Lab Share Price Today, Parnax Lab Stock News or a fresh Parnax Lab Share Price Update, Univest brings the day’s price action together with fundamental analysis, peer benchmarking and sector context in one place. That makes it easier to track whether a sharp one-day move is simply notable price action or part of a broader pattern worth monitoring.

Frequently Asked Questions

Why is Parnax Lab Share Price falling today?

Ans. Parnax Lab Share Price fell because the stock traded at Rs 116.50 versus the previous close of Rs 129.35, a decline of 9.93%. The supplied data confirms the price move and trading range, but it does not identify a company-specific.

What is Parnax Lab Share Price Today?

Ans. Parnax Lab Share Price Today is Rs 116.50. The stock is down Rs 12.85 from the previous close of Rs 129.35, and the day’s trading range in the supplied data runs from Rs 114.50 to Rs 118.

How much did Parnax Lab stock decline in today’s session?

Ans. Parnax Lab stock declined 9.93% in the session covered by this update. In absolute terms, that is a fall of Rs 12.85, with the price moving from the previous close of Rs 129.35 to Rs 116.50.

What were the day high, day low and opening price for Parnax Lab?

Ans. The stock opened at Rs 118, which was also the day’s high in the supplied data. The intraday low was Rs 114.50, showing that the counter remained under pressure after the opening print.

What is the market capitalisation of Parnax Lab?

Ans. Parnax Lab has a market capitalisation of Rs 148.57 crore. That places it in the Micro Cap category in the supplied classification and slightly above the same-industry median market cap of Rs 137.80 crore.

Is Parnax Lab expensive compared with its industry on P/E?

Ans. Parnax Lab’s P/E ratio is 16.63, which is below the same-industry median of 26.47 and below the average of 40.28. On the supplied benchmark numbers, the stock is not positioned near the expensive end of the industry range.

How does Parnax Lab compare on P/B ratio?

Ans. The company’s P/B ratio is 1.55. That is below the industry median of 1.77 and below the industry average of 2.33, indicating that its valuation on book value is also lower than central benchmark levels.

What do Parnax Lab’s ROE and ROCE indicate?

Ans. Parnax Lab reports ROE of -1.11% and ROCE of 5.83%. Those figures are below the same-industry medians of 9.91% and 12.79, so the supplied profitability metrics are weaker than broader benchmark profitability levels.

What are the EPS and dividend yield of Parnax Lab?

Ans. Parnax Lab’s EPS is Rs 7.78, which represents earnings attributable to each share on the supplied basis. Its dividend yield is 0, so the current dataset does not show a historical payout relative to the share price.

Why is Parnax Lab Share Price in focus on Univest?

Ans. Parnax Lab Share Price is in focus on Univest because the stock fell 9.93% in a single session, clearing the event screen for its Micro Cap category. The move also stands out against below-median valuation and below-benchmark profitability metrics.